Archive for the 'Prostate Cancer' Category
How To Prevent Prostate Problems and Diseases?
Article Health And Fitness | How To Prevent Prostate Problems and Diseases?How To Prevent Prostate Problems and Diseases?
By: Cindy Heller
The prostate gland is an essential part of a male’s reproductive system. It secretes fluids that aid in the transportation and activation of sperm. The pro…
Lower PSA Values Found In Overweight And Obese Men, Even Before Diagnosis Of Prostate Cancer
Men who are overweight or obese have lower concentrations of prostate-specific antigen (PSA) in their blood than their normal-weight counterparts, according to a new study led by Duke University Medical Center researchers.The finding echoes earlier results on PSA concentrations found in obese and ov…
Beyond The summary: Pharmacology And New Perspectives Of Angiotensin II Receptor Blocker In Prostate Cancer Treatment
UroToday.com - AT1 receptor blockers (ARBs) possessing our experimental demonstrations may offer clinical efficacy in patients with hormone refractory prostate cancer (HRPC).In practice, we conducted a pilot clinical study to examine whether an ARB (candesartan) was able to clinically elicit an anti…
ASCO GU 2008 - The Role Of MicroRNA In Prostate Tumor Biology
UroToday.com - Dr. Nelson discussed that androgen-independent CaP progression is not really independent of androgens. Using microarray based expression profiling in LNCaP cells, gene expression following androgen deprivation therapy was performed. They sought to identify the regulatory cascade gover…
ASCO GU 2008 - Secondary Androgen Deprivation: Treating The Prostate Specific Antigen Or The Patient
UroToday.com - Dr. Oh reviewed the past and present of secondary hormonal therapies. He showed patient cases of sequential secondary therapies with outcomes supporting the heterogeneity of CaP. Some patients metastasize thereupon develop castration resistant prostate cancer (CRPC) while others have …
ASCO GU 2008 - Prostate Stem Cell Insight Into Tumor Initiation
UroToday.com - John Isaacs, Johns Hopkins discussed stem cell biology. Cancer is caused by a series of genetic changes (both germ line and somatic). Genetic instability can occur even in cancer cells, influencing their behavior. He cited the Gleason scoring system as an example of phenotypic heterog…
Preliminary Phase II Results Of Abiraterone Acetate In Patients With Castration-resistant Metastatic Prostate Cancer
UroToday.com - Dr. Danila, spoke about abiraterone acetate (AA), an oral and irreversible inhibitor of CYP17 that decreases testosterone and DHT levels to undetectable. The study presented sought to determine the proportion of patients achieving a PSA decline of >50% and to assess toxicity. It wa…
ASCO GU 2008 - Nutrition And Prostate Cancer
UroToday.com - June Chan from UCSF presented on Nutritional Epidemiology of Prostate Cancer. In a population migration study, low-risk CaP populations moving to a high-risk area shifted to a higher risk profile. Chinese men in China had a CaP risk of 3/100,000, but after moving to the US that increa…
ASCO GU 2008 - Correlating Androgen Levels And Steroidogenic Enzyme Expression In Castration-Resistant Prostate Cancer (CRPC) Metastases
UroToday.com - Dr. Mostaghel reviewed the potential sources of tissue androgens from the androgen metabolic pathway. that includes the uptake and conversion of circulating adrenal androgens, and the de novo androgen biosynthesis of androgens from cholesterol, progesterone or earlier precursors.Tumor…
ASCO GU 2008 - Androgen Suppression And Radiation Versus Radiation For Prostate Cancer
UroToday.com - that study sought to compare survival in a prospective randomized trial of radiotherapy (XRT) alone vs. XRT with 6 months of ADT. 206 men were accrued and randomized. They all had at least one unfavorable-risk factor. 70 Gy of XRT was given. The lymph nodes were not treated. ADT was 2…
Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety And Efficacy info With Picoplatin In Metastatic Prostate Cancer Patients
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, announced that it is presenting safety and efficacy notes in prostate cancer patients from its Phase 1 study of picoplatin, the Company’s lead product candidate, at the 2008 Genitourinary (GU) Cancers Symp…













